Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALURW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ALLURION TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ALLURION TECHNOLOGIES's regulatory disclosures and financial reporting.
Allurion Technologies, Inc. describes its business as a metabolically focused weight loss platform built around the Allurion Program, which combines the swallowable Allurion Smart Capsule gastric balloon with an AI-powered Virtual Care Suite for remote monitoring and behavior change.
The company highlights more than 200,000 patients treated across over 50 countries and positions its program as complementary to GLP-1 drugs. It reports FDA PMA approval in the United States for the Allurion Gastric Balloon System for adults with obesity, enabling U.S. commercialization. Recent financing steps include a November 2025 private placement and a February 2026 warrant inducement that raised cash but added new warrants.
Allurion also discloses NYSE minimum market-capitalization non-compliance and ongoing appeals of delisting determinations, with its common stock now trading on the OTC market and plans to seek a higher-tier OTC listing. The company emphasizes a large obesity market opportunity, a broad patent and trademark portfolio, and a strategy focused on global expansion, U.S. launch, and a path to profitability.